|Company Name||Abbott Laboratories|
On May 14, 2020, the U.S. Food and Drug Administration announced that early data "suggest[s] potential inaccurate results from using the Abbott ID NOW point-of-care test to diagnose COVID-19 . . . and [that] the test may return false negative results."
On this news, Abbott's share price fell sharply during intraday trading on May 15, 2020.
Submit Your Information
If you suffered a loss on your Abbott Laboratories investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.